Association of Non-Alcoholic Fatty Liver Disease and Metabolic-Associated Fatty Liver Disease with COVID-19-Related Intensive Care Unit Outcomes: A Systematic Review and Meta-Analysis
暂无分享,去创建一个
R. Kashyap | Kaanthi Rama | S. Surani | V. Bansal | S. Reddy | Yatinder Bains | Harsha Pattnaik | Rakhtan K Qasba | T. Dacosta | G. Jagirdhar | A. Banga | P. Elmati | A. Bucharles
[1] R. Kashyap,et al. Association of non-alcoholic fatty liver and metabolic-associated fatty liver with COVID-19 outcomes: A systematic review and meta-analysis , 2023, World journal of gastroenterology.
[2] Xiaoli Ma,et al. Comprehensive Analysis of N6-Methyladenosine (m6A) RNA Methylation Regulators and Tumour Microenvironment Cell Infiltration Involving Prognosis and Immunotherapy in Gastroesophageal Adenocarcinomas , 2022, Canadian journal of gastroenterology & hepatology.
[3] U. Hayat,et al. The Association of Metabolic-Associated Fatty Liver Disease with Clinical Outcomes of COVID-19: A Systematic Review and Meta-Analysis , 2022, Kansas journal of medicine.
[4] S. Ozturk,et al. Prevalence and Prognostic Importance of High Fibrosis-4 Index in COVID-19 Patients , 2022, International journal of clinical practice.
[5] Jinkwon Kim,et al. Association between the fatty liver index and the risk of severe complications in COVID-19 patients: a nationwide retrospective cohort study , 2022, BMC Infectious Diseases.
[6] K. Madan,et al. Is Fatty Liver Associated with Increased Mortality and Morbidity in Coronavirus Disease 2019 (COVID-19) Pneumonia? , 2022, Journal of Clinical and Experimental Hepatology.
[7] A. Vince,et al. Association of Nonalcoholic Fatty Liver Disease With COVID-19 Severity and Pulmonary Thrombosis: CovidFAT, a Prospective, Observational Cohort Study , 2022, Open forum infectious diseases.
[8] D. Kershenobich-Stalnikowitz,et al. NAFLD determined by Dallas Steatosis Index is associated with poor outcomes in COVID-19 pneumonia: a cohort study , 2022, Internal and Emergency Medicine.
[9] D. Mutter,et al. Abnormal liver tests and non-alcoholic fatty liver disease predict disease progression and outcome of patients with COVID-19 , 2022, Clinics and Research in Hepatology and Gastroenterology.
[10] Yongli Zheng,et al. Not Only High Number and Specific Comorbidities but Also Age Are Closely Related to Progression and Poor Prognosis in Patients With COVID-19 , 2022, Frontiers in Medicine.
[11] S. Kashyap,et al. Impact of Metabolic Syndrome on Severity of COVID-19 Illness. , 2022, Metabolic syndrome and related disorders.
[12] M. Iftikhar,et al. Outcomes of Nonalcoholic Fatty Liver Disease In Covid Positive Diabetic Patients: Cross Sectional Study , 2021, Pakistan Journal of Medical & Health Sciences.
[13] Guo-bao Wu,et al. Association between non‐alcoholic fatty liver disease with the susceptibility and outcome of COVID‐19: A retrospective study , 2021, Journal of cellular and molecular medicine.
[14] A. Koyanagi,et al. Non-alcoholic Fatty Liver Disease and COVID-19 Susceptibility and Outcomes: a Korean Nationwide Cohort , 2021, Journal of Korean medical science.
[15] L. Gerber,et al. Independent Predictors of Mortality Among Patients With NAFLD Hospitalized With COVID‐19 Infection , 2021, Hepatology communications.
[16] Jian Wang,et al. Risk of severe illness of COVID‐19 patients with NAFLD and increased NAFLD fibrosis scores , 2021, Journal of clinical laboratory analysis.
[17] L. Tamariz,et al. Metabolic surgery may protect against admission for COVID-19 in persons with nonalcoholic fatty liver disease , 2021, Surgery for Obesity and Related Diseases.
[18] Zachary P. Fricker,et al. Radiographic Hepatic Steatosis Is Not Associated With Key Clinical Outcomes Among Patients Hospitalized With COVID-19 , 2021, Gastroenterology research.
[19] M. Balakrishnan,et al. Global Epidemiology of Chronic Liver Disease , 2021, Clinical liver disease.
[20] C. Fierbinţeanu-Braticevici,et al. The Impact of Increased Fib-4 Score in Patients with Type II Diabetes Mellitus on COVID-19 Disease Prognosis , 2021, Medicina.
[21] R. Pranata,et al. Fibrosis-4 index and mortality in coronavirus disease 2019: a meta-analysis , 2021, European journal of gastroenterology & hepatology.
[22] J. Mayerle,et al. Liver function test abnormalities at hospital admission are associated with severe course of SARS-CoV-2 infection: a prospective cohort study , 2021, Gut.
[23] A. Ciudin,et al. The role of liver steatosis as measured with transient elastography and transaminases on hard clinical outcomes in patients with COVID-19 , 2021, Therapeutic advances in gastroenterology.
[24] Fateen Ata,et al. NAFLD is a predictor of liver injury in COVID-19 hospitalized patients but not of mortality, disease severity on the presentation or progression – The debate continues , 2020, Journal of Hepatology.
[25] Yuanlin Song,et al. COVID-19-associated gastrointestinal and liver injury: clinical features and potential mechanisms , 2020, Signal Transduction and Targeted Therapy.
[26] M. Thursz,et al. In-hospital mortality is associated with inflammatory response in NAFLD patients admitted for COVID-19 , 2020, PloS one.
[27] J. A. Cook,et al. Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study , 2020, Journal of Hepatology.
[28] Chia-Yang Hsu,et al. Hepatic Steatosis Is Associated with Increased Disease Severity and Liver Injury in Coronavirus Disease-19 , 2020, Digestive Diseases and Sciences.
[29] A. Branch,et al. Predictors of Outcomes of COVID-19 in Patients With Chronic Liver Disease: US Multi-center Study , 2020, Clinical Gastroenterology and Hepatology.
[30] E. Mayo-Wilson,et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews , 2020, BMJ.
[31] A. Mari,et al. Nonalcoholic fatty liver disease is associated with COVID-19 severity independently of metabolic syndrome: a retrospective case-control study , 2020, European journal of gastroenterology & hepatology.
[32] Qianghu Wang,et al. Implications of liver injury in risk-stratification and management of patients with COVID-19 , 2020, Hepatology International.
[33] Jian Wang,et al. Clinical Features of Patients With COVID‐19 With Nonalcoholic Fatty Liver Disease , 2020, Hepatology communications.
[34] Yangang Wang,et al. Comorbidities and the risk of severe or fatal outcomes associated with coronavirus disease 2019: A systematic review and meta-analysis , 2020, International Journal of Infectious Diseases.
[35] P. Hegyi,et al. Obesity is a risk factor for developing critical condition in COVID‐19 patients: A systematic review and meta‐analysis , 2020, Obesity reviews : an official journal of the International Association for the Study of Obesity.
[36] B. Hamm,et al. The role of visceral adiposity in the severity of COVID-19: Highlights from a unicenter cross-sectional pilot study in Germany , 2020, Metabolism.
[37] V. Wong,et al. Liver injury is independently associated with adverse clinical outcomes in patients with COVID-19 , 2020, Gut.
[38] H. Tilg,et al. Liver stiffness by transient elastography accompanies illness severity in COVID-19 , 2020, BMJ open gastroenterology.
[39] H. Krumholz,et al. Extrapulmonary manifestations of COVID-19 , 2020, Nature Medicine.
[40] D. Wong,et al. Impact of chronic liver disease on outcomes of hospitalized patients with COVID‐19: A multicentre United States experience , 2020, Liver international : official journal of the International Association for the Study of the Liver.
[41] M. Zheng,et al. Metabolic‐associated fatty liver disease is associated with severity of COVID‐19 , 2020, Liver international : official journal of the International Association for the Study of the Liver.
[42] Roger Williams,et al. Is the increased risk for MAFLD patients to develop severe COVID-19 linked to perturbation of the gut-liver axis? , 2020, Journal of Hepatology.
[43] Ashish Kumar,et al. Metabolic dysfunction associated fatty liver disease increases risk of severe Covid-19 , 2020, Diabetes & Metabolic Syndrome: Clinical Research & Reviews.
[44] H. Tilg,et al. From NAFLD to MAFLD: when pathophysiology succeeds , 2020, Nature Reviews Gastroenterology & Hepatology.
[45] Feng Gao,et al. Metabolic associated fatty liver disease increases COVID-19 disease severity in non-diabetic patients. , 2020, Journal of gastroenterology and hepatology.
[46] M. Zheng,et al. Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores , 2020, Gut.
[47] Sittichai Tantipasawasin. Coronavirus disease (COVID-19) Pandemic , 2020 .
[48] M. Zheng,et al. Younger patients with MAFLD are at increased risk of severe COVID-19 illness: A multicenter preliminary analysis , 2020, Journal of Hepatology.
[49] Yizhen Chen,et al. Guidelines for the diagnosis and treatment of coronavirus disease 2019 (COVID-19) in China. , 2020, Global health & medicine.
[50] C. Rentsch,et al. Covid-19 Testing, Hospital Admission, and Intensive Care Among 2,026,227 United States Veterans Aged 54–75 Years , 2020, medRxiv.
[51] V. Wong,et al. A new definition for metabolic associated fatty liver disease: an international expert consensus statement. , 2020, Journal of hepatology.
[52] Jing Xu,et al. Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study , 2020, Journal of Hepatology.
[53] L. Luzi,et al. Influenza and obesity: its odd relationship and the lessons for COVID-19 pandemic , 2020, Acta Diabetologica.
[54] G. Herrler,et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.
[55] K. Yuen,et al. Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.
[56] Y. Hu,et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.
[57] Douglas G. Altman,et al. Analysing data and undertaking meta‐analyses , 2019, Cochrane Handbook for Systematic Reviews of Interventions.
[58] M. Page,et al. Considering bias and conflicts of interest among the included studies , 2019, Cochrane Handbook for Systematic Reviews of Interventions.
[59] F. Tacke,et al. Macrophages in obesity and non-alcoholic fatty liver disease: Crosstalk with metabolism , 2019, JHEP reports : innovation in hepatology.
[60] A. Charlett,et al. Study quality assessment tools , 2016 .
[61] Jiming Liu,et al. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range , 2014, BMC Medical Research Methodology.
[62] Michele Tarsilla. Cochrane Handbook for Systematic Reviews of Interventions , 2010, Journal of MultiDisciplinary Evaluation.
[63] Z. Younossi,et al. Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome. , 2008, Cleveland Clinic journal of medicine.
[64] Douglas G. Altman,et al. Chapter 9: Analysing Data and Undertaking Meta-Analyses , 2008 .
[65] E. Reyes,et al. Association of nafld and mafld with mortality in patients hospitalized with COVID-19 infection , 2021 .